{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:42:33Z","timestamp":1792190553490,"version":"4.4.0"},"reference-count":33,"publisher":"Bioscientifica","issue":"11","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but can induce immune-related adverse events, most commonly hypothyroidism. The reversibility of ICI-induced hypothyroidism and the potential for discontinuing levothyroxine (LT4) treatment remain unclear. This retrospective study analyzed patients who developed hypothyroidism due to ICI treatment and were prescribed LT4 at a tertiary referral hospital from January 2016 to March 2024. Among 3,753 patients treated with ICIs, 254 (6.8%) developed hypothyroidism requiring LT4 treatment. Of the 184 patients who discontinued ICI, only 10 (5.4%) discontinued LT4 during a median follow-up of 13.2 months, while none did among those continuing ICIs. Multivariable Cox regression analysis revealed that the use of ICIs in early-stage cancer (HR 13.40, 95% CI: 1.99\u201390.06, P = 0.008) and TSH &amp;lt;20 \u03bcIU\/mL before starting LT4 (HR 15.16, 95% CI: 2.17\u2013105.85, P = 0.006) significantly increased the likelihood of discontinuing LT4. These findings suggest that while recovery from ICI-induced hypothyroidism is uncommon, patients treated for early-stage cancer and those with lower TSH levels before starting LT4 may have a greater likelihood of recovery.<\/jats:p>","DOI":"10.1530\/erc-25-0138","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:10:37Z","timestamp":1762513837000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":2,"title":["Reversibility of immune checkpoint inhibitor-induced hypothyroidism"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9992-6273","authenticated-orcid":true,"given":"Jeongmin","family":"Seo","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9765-9340","authenticated-orcid":true,"given":"Min Joo","family":"Kim","sequence":"additional","affiliation":[{"name":"2"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minsu","family":"Kang","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hee","family":"Jung","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koung Jin","family":"Suh","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Won","family":"Kim","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Wook","family":"Lee","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Seok","family":"Lee","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Wook","family":"Cho","sequence":"additional","affiliation":[{"name":"3"},{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Moon","sequence":"additional","affiliation":[{"name":"2"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"2026070909434196000_bib1","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1586\/14737140.2014.929501","article-title":"Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis","volume":"14","author":"Abdel-Rahman","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"2026070909434196000_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"2026070909434196000_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026070909434196000_bib4","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026070909434196000_bib5","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1089\/thy.2014.0111","article-title":"A new strategy to estimate levothyroxine requirement after total thyroidectomy for benign thyroid disease","volume":"24","author":"Di Donna","year":"2014","journal-title":"Thyroid"},{"key":"2026070909434196000_bib6","doi-asserted-by":"crossref","first-page":"e008591","DOI":"10.1136\/jitc-2023-008591","article-title":"Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update","volume":"12","author":"Fletcher","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026070909434196000_bib7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"2026070909434196000_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026070909434196000_bib9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41574-021-00625-8","article-title":"Primary hypothyroidism and quality of life","volume":"18","author":"Hegedus","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"2026070909434196000_bib10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2026070909434196000_bib11","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1530\/EJE-14-0198","article-title":"Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors","volume":"171","author":"Illouz","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"2026070909434196000_bib12","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1089\/thy.2014.0028","article-title":"Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement","volume":"24","author":"Jonklaas","year":"2014","journal-title":"Thyroid"},{"key":"2026070909434196000_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233596","article-title":"Clinical factors predicting the successful discontinuation of hormone replacement therapy in patients diagnosed with primary hypothyroidism","volume":"15","author":"Jung","year":"2020","journal-title":"PLoS One"},{"key":"2026070909434196000_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J Endocr Soc"},{"key":"2026070909434196000_bib15","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1089\/thy.2020.0075","article-title":"Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"2026070909434196000_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070909434196000_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg0675","article-title":"Clonally expanded, thyrotoxic effector CD8(+) T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis","volume":"15","author":"Lechner","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026070909434196000_bib18","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1089\/thy.2018.0014","article-title":"Levothyroxine replacement therapy and overuse: a timely diagnostic approach","volume":"28","author":"Livadas","year":"2018","journal-title":"Thyroid"},{"key":"2026070909434196000_bib19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2026070909434196000_bib20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1089\/thy.2021.0685","article-title":"Optimal thyroid hormone replacement dose in immune checkpoint inhibitor-associated hypothyroidism is distinct from Hashimoto\u2019s thyroiditis","volume":"32","author":"Mosaferi","year":"2022","journal-title":"Thyroid"},{"key":"2026070909434196000_bib21","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1089\/thy.2020.0032","article-title":"Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer","volume":"30","author":"Muir","year":"2020","journal-title":"Thyroid"},{"key":"2026070909434196000_bib22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"2026070909434196000_bib23","doi-asserted-by":"crossref","first-page":"11057","DOI":"10.1200\/JCO.2024.42.16_suppl.11057","article-title":"Overlapping and non-overlapping indications for checkpoint inhibitors in the US","volume":"42","author":"Paul","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026070909434196000_bib24","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cen.14135","article-title":"Thyroid disorders in programmed death 1 inhibitor-treated patients: is previous therapy with tyrosine kinase inhibitors a predisposing factor?","volume":"92","author":"Sbardella","year":"2020","journal-title":"Clin Endocrinol"},{"key":"2026070909434196000_bib25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40261-023-01254-x","article-title":"Spending, utilization, and price trends for immune checkpoint inhibitors in US medicaid programs: an empirical analysis from 2011 to 2021","volume":"43","author":"Shin","year":"2023","journal-title":"Clin Drug Investig"},{"key":"2026070909434196000_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/imr.13247","article-title":"Immune-related adverse events after immune check point inhibitors: understanding the intersection with autoimmunity","volume":"318","author":"Singh","year":"2023","journal-title":"Immunol Rev"},{"key":"2026070909434196000_bib27","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review","volume":"9","author":"Stelmachowska-Banas","year":"2020","journal-title":"Endocr Connect"},{"key":"2026070909434196000_bib28","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJM199202203260803","article-title":"Disappearance of thyrotropin-blocking antibodies and spontaneous recovery from hypothyroidism in autoimmune thyroiditis","volume":"326","author":"Takasu","year":"1992","journal-title":"N Engl J Med"},{"key":"2026070909434196000_bib29","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2018.0047","article-title":"New NCCN guidelines: Recognition and management of immunotherapy-related toxicity","volume":"16","author":"Thompson","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"2026070909434196000_bib30","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with Anti-PD-1 therapy for advanced non-small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026070909434196000_bib31","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1210\/clinem\/dgad670","article-title":"Risk and incidence of endocrine immune-related adverse effects under checkpoint inhibitor mono- or combination therapy in solid tumors: a meta-analysis of randomized controlled trials","volume":"109","author":"Vardarli","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909434196000_bib32","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026070909434196000_bib33","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3803\/EnM.2020.906","article-title":"Characteristics of immune-related thyroid adverse events in patients treated with PD-1\/PD-L1 inhibitors","volume":"36","author":"Yoon","year":"2021","journal-title":"Endocrinol Metab"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/11\/ERC-25-0138.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/11\/ERC-25-0138.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0138\/505457\/erc-25-0138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0138\/505457\/erc-25-0138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:43:51Z","timestamp":1783604631000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/11\/e250138\/75467\/Reversibility-of-immune-checkpoint-inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0138","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"article-number":"e250138"}}